CN112915160A - Medicine for treating poultry egg allergic diseases and processing technology thereof - Google Patents
Medicine for treating poultry egg allergic diseases and processing technology thereof Download PDFInfo
- Publication number
- CN112915160A CN112915160A CN201911245945.9A CN201911245945A CN112915160A CN 112915160 A CN112915160 A CN 112915160A CN 201911245945 A CN201911245945 A CN 201911245945A CN 112915160 A CN112915160 A CN 112915160A
- Authority
- CN
- China
- Prior art keywords
- parts
- eggs
- treating
- medicament
- poultry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 244000144977 poultry Species 0.000 title claims abstract description 55
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 53
- 238000012545 processing Methods 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title description 7
- 235000013601 eggs Nutrition 0.000 claims abstract description 109
- 239000002994 raw material Substances 0.000 claims abstract description 37
- 241000931705 Cicada Species 0.000 claims abstract description 32
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 32
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 32
- 241001523681 Dendrobium Species 0.000 claims abstract description 32
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 32
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 32
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 32
- 240000000147 Torreya grandis Species 0.000 claims abstract description 32
- 235000016410 Torreya grandis Nutrition 0.000 claims abstract description 32
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 32
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 32
- 240000006766 Cornus mas Species 0.000 claims abstract description 29
- 235000012874 Phaseolus calcaratus Nutrition 0.000 claims abstract description 22
- 238000002791 soaking Methods 0.000 claims abstract description 19
- 244000237330 gutta percha tree Species 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 13
- 241001233061 earthworms Species 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 7
- 235000013345 egg yolk Nutrition 0.000 claims description 28
- 210000002969 egg yolk Anatomy 0.000 claims description 28
- 241000272525 Anas platyrhynchos Species 0.000 claims description 27
- 241000286209 Phasianidae Species 0.000 claims description 27
- 241000272814 Anser sp. Species 0.000 claims description 24
- 241000243684 Lumbricus Species 0.000 claims description 16
- 102000002322 Egg Proteins Human genes 0.000 claims description 14
- 108010000912 Egg Proteins Proteins 0.000 claims description 14
- 241000208688 Eucommia Species 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 210000004317 gizzard Anatomy 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 8
- 240000007594 Oryza sativa Species 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 6
- 238000010000 carbonizing Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 235000009566 rice Nutrition 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 241000361919 Metaphire sieboldi Species 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 244000118681 Iresine herbstii Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 241000142975 Cornaceae Species 0.000 claims description 3
- 210000003038 endothelium Anatomy 0.000 claims description 3
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 2
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 244000017020 Ipomoea batatas Species 0.000 claims description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 2
- 235000010582 Pisum sativum Nutrition 0.000 claims description 2
- 240000004713 Pisum sativum Species 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 244000040738 Sesamum orientale Species 0.000 claims description 2
- 240000003829 Sorghum propinquum Species 0.000 claims description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 238000010563 solid-state fermentation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 7
- 241000628997 Flos Species 0.000 claims 1
- 241000825107 Hierochloe Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 abstract description 13
- 208000010668 atopic eczema Diseases 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000000172 allergic effect Effects 0.000 abstract description 5
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 238000000586 desensitisation Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000007815 allergy Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 240000000275 Persicaria hydropiper Species 0.000 description 3
- 235000017337 Persicaria hydropiper Nutrition 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000001093 holography Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000035239 Synesthesia Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
- C12G3/021—Preparation of other alcoholic beverages by fermentation of botanical family Poaceae, e.g. wheat, millet, sorghum, barley, rye, or corn
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
- C12G3/021—Preparation of other alcoholic beverages by fermentation of botanical family Poaceae, e.g. wheat, millet, sorghum, barley, rye, or corn
- C12G3/022—Preparation of other alcoholic beverages by fermentation of botanical family Poaceae, e.g. wheat, millet, sorghum, barley, rye, or corn of botanical genus Oryza, e.g. rice
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
- C12G3/026—Preparation of other alcoholic beverages by fermentation with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides, added before or during the fermentation stage; with flavouring ingredients added before or during the fermentation stage
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicament for treating allergic diseases of poultry eggs and a processing technology thereof, wherein the medicament comprises the following components in parts by weight: 2-9 parts of poultry eggs, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates; soaking the raw materials in water, drying in the shade, crushing, extracting, adding special white spirit, baking, and performing secondary nano-crushing to obtain a finished medicinal powder; the invention adopts a treatment idea of repairing an immune system, and treats allergic diseases by using corresponding poultry eggs aiming at different allergens causing allergic symptoms.
Description
Technical Field
The invention relates to the technical field of medicines, health-care foods and food additives, in particular to a medicine for treating poultry egg allergic diseases and a processing technology thereof.
Background
Allergic diseases are also called allergic diseases, and common allergic diseases comprise allergic dermatitis, allergic rhinitis, allergic asthma, anaphylactic shock and the like, and are common diseases and frequently encountered diseases in clinic. With the development of socio-economy, the change of dietary structure and living environment, the incidence rate of allergic diseases in the world is rising year by year, according to the statistical data released by the World Allergy Organization (WAO), the incidence rate of allergic diseases is increased by at least 3 times in nearly 30 years, the global total disease rate is up to 22 percent at present, and 50 percent of population in industrialized countries is expected to suffer from the allergic diseases after 20 years. The World Health Organization (WHO) has classified allergic diseases as one of three major diseases requiring intensive research and prevention in the 21 st century.
Allergic diseases have several particularities that make them a globally problematic health problem.
First, allergenic protozoa are closely related, forming a potential health and life threat that is difficult to prevent.
An allergen, also known as an allergen, is a non-parasitic antigen that can promote type I hypersensitivity in atopic individuals.
The prevalence and commonness of allergens may lead allergic patients to accidentally contact, inhale or eat the allergens, and then allergic reactions, even shock and acute death occur.
Secondly, allergic patients can develop diseases when encountering allergens, and are easy to repeatedly attack and difficult to cure. Peanut and nut food allergy patients often suffer from juvenile onset, are lifelong, and serious patients can cause laryngeal edema and suffocation due to transient overexcitation reaction, thereby being life-threatening.
The modern medicine mainly comprises three types of medicament treatment, immunosuppressant and desensitization treatment for treating allergy. The drug therapy mainly comprises antihistamines, mast cell stabilizers and calcium agents, and is used for relieving and inhibiting symptoms caused by allergy by pharmacology, but the symptoms cannot be completely cured and are accompanied by side effects such as lethargy, liver and kidney injury, immune injury, hormone rebound and the like. The immunosuppressant is a drug having an inhibitory effect on the immune response of the body, and can inhibit the proliferation and function of cells (macrophages such as T cells and B cells) associated with the immune response, and reduce the immune response of antibodies. Desensitization therapy, also known as specific immunotherapy or desensitization therapy, is characterized in that after an allergen of an allergic disease patient is clinically determined, the allergen is prepared into an allergen extracting solution and prepared into preparations with different concentrations, the preparations are repeatedly injected or sublingually taken or repeatedly contacted with the patient through other administration routes, the dose is from small to large, the concentration is from low to high, after a maintenance dose is reached, a sufficient treatment course is maintained, so that the tolerance of the patient to the allergen is improved, and when the allergen is contacted again, the allergic phenomenon is reduced or no longer generated. Desensitization treatment for allergic diseases such as allergic rhinitis, allergic asthma, allergic dermatitis and the like is often applied, and clinical common desensitization treatment is different according to administration modes: injection desensitization, sublingual buccal desensitization, desensitization paste and the like.
Desensitization therapy is not suitable for use in the following conditions:
(1) patients with severe autoimmune disease or malignancy are co-morbid. For example, patients with serious immune diseases such as collagen diseases, autoimmune diseases, lymphoproliferative diseases and the like are contraindicated to avoid aggravating the disease conditions; it should be used with cautions for severe atopic dermatitis.
(2) Patients who are not suitable for adrenalin treatment, such as hypertension, coronary heart disease, and the like, are contraindicated. Because desensitization therapy may cause systemic anaphylaxis and even anaphylactic shock, these patients cannot be rescued with epinephrine, resulting in a greatly increased risk. Desensitization therapy is also contraindicated in patients treated with beta blockers.
(3) Patients with poor compliance are not suitable for use. Successful immunotherapy requires patients to be matched with physicians and receive treatment for a long period of time and regularly, and desensitization treatment generally requires 3-5 years to complete a treatment course, for example, patients lack cooperation or have serious psychological disorders and should not be desensitized.
The present invention differs from the above-described method of treating allergy by the therapeutic concept of restoring the immune system.
Modern biology also considers that humans are products of nature and life is a product of the development of nature to a certain stage. After life has been generated, it has undergone an evolutionary development process for hundreds of millions of years. Modern biology believes that all life forms on earth are of the simplest single-celled origin. Various organisms of different types exist, even if the difference between the high level and the low level is very different, a certain genetic relationship exists, so that the phenomena of 'heaven-person correspondence' and 'synaesthesia' exist. In TCM, it is the result of this kind of "synesthesia" that every zang-fu organ of the human body has its own specific herb.
Evaluation wine of 'materia medica shigao' of Tang Dynasty collection apparatus can 'dredge blood vessels, thicken intestinal tracts, moisten skin, disperse moisture, eliminate love and anger and promote smooth love'. For the first time, the statement that "wine is the best of all herbs" is described in Han Shu, food and beverage Zhi: the food is prepared from wheat salt and delicacies; wine, the long of hundreds of herbs and good of Jiahui. Wine has been described in the Huangdi's classic, which is a long-standing source in China. For example, Ling Shu & Lun Yong: the spirit of wine, essence of water and grain, and liquid of cooked grain are also the vigorous thing. Wine is also a kind of fire in water. Enter heart and kidney meridians. Heart and kidney, nature and life. The hit door of double repair is also. Enter heart and kidney meridians. The pulse is smooth. Dredging the channels and collaterals. With drug property, it reaches the focus of infection. The night is full of illness. Therefore, wine is the best of all herbs.
The basic principle of the universe holography is as follows: in view of the sum of the latent obvious information, any part contains the whole information. Generally, holography is the ability to obtain all the information of an entire organism from any part of the organism. From a biological point of view, the holography is that the whole information of an organism can be obtained from any part of the organism. This is why we emphasize that the parts related by allergens must be in one-to-one correspondence as sources of compatibility.
Disclosure of Invention
The invention aims to provide a medicament for treating poultry egg allergic diseases and a processing technology thereof, and aims to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a medicine for treating poultry egg allergic diseases comprises the following components in parts by weight: 2-9 parts of poultry eggs, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
In a preferred embodiment of the present invention, the poultry eggs include, but are not limited to, chicken eggs, duck eggs, goose eggs, quail eggs, and egg-containing products.
As a preferred technical scheme, the poultry eggs are eggs.
As a preferable technical scheme of the invention, the medicine comprises the following specific components: 2-9 parts of eggs, 8-22 parts of egg yolk, 4-14 parts of endothelium corneum gigeriae galli, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia root, 4-14 parts of eucommia bark, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seed and 3-10 parts of black date.
As a preferable technical scheme of the invention, the medicine comprises the following specific components: 8 parts of eggs, 12 parts of egg yolk, 13 parts of chicken gizzard membrane, 10 parts of earthworm, 20 parts of dendrobium, 20 parts of cassia twig, 14 parts of cicada slough, 14 parts of divaricate saposhnikovia root, 13 parts of eucommia bark, 6 parts of dogwood, 10 parts of longan, 10 parts of red bean, 12 parts of Chinese torreya seed and 8 parts of black date.
As a preferred technical scheme, the poultry eggs are duck eggs.
As a preferable technical scheme of the invention, the medicine comprises the following specific components: 2-9 parts of duck eggs, 10-20 parts of duck egg yolks, 4-10 parts of duck gizzard skins, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
As a preferable technical scheme of the invention, the medicine comprises the following specific components: 7 parts of duck eggs, 15 parts of duck egg yolks, 10 parts of duck gizzards, 8 parts of lumbricus, 16 parts of dendrobium, 17 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 10 parts of eucommia ulmoides, 6 parts of dogwood, 6 parts of longan, 8 parts of phaseolus calcaratus, 10 parts of Chinese torreya seeds and 5 parts of black dates.
As a preferred technical scheme, the poultry eggs are goose eggs.
As a preferable technical scheme of the invention, the medicine comprises the following specific components: 2-9 parts of goose eggs, 8-22 parts of goose egg yolk, 4-16 parts of goose gizzard-membrane, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia root, 4-14 parts of eucommia bark, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black date.
As a preferable technical scheme of the invention, the medicine comprises the following specific components: 7 parts of hen eggs, 14 parts of egg yolk, 10 parts of chicken gizzard-membrane, 8 parts of earthworm, 15 parts of dendrobium, 17 parts of cassia twig, 10 parts of cicada slough, 12 parts of divaricate saposhnikovia root, 10 parts of eucommia bark, 8 parts of dogwood, 11 parts of longan, 7 parts of phaseolus calcaratus, 6 parts of Chinese torreya seed and 10 parts of black date.
As a preferred technical scheme, the poultry eggs are quail eggs.
As a preferred technical scheme, the feed comprises, by weight, 2-9 parts of quail eggs, 12-22 parts of quail egg yolks, 4-14 parts of quail gizzard-membrane, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwoods, 2-12 parts of longans, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
As a preferred technical scheme, the feed comprises 8 parts of quail eggs, 14 parts of quail egg yolks, 10 parts of quail gizzard-skins, 8 parts of earthworms, 22 parts of dendrobium, 18 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 12 parts of eucommia ulmoides, 6 parts of dogwood, 8 parts of longan, 7 parts of red beans, 7 parts of Chinese torreya seeds and 7 parts of black dates.
As a preferred technical scheme, the invention also provides a processing technology of the medicament for treating the allergic diseases of the animal meat, which comprises the following steps:
s1, weighing the raw materials according to the weight proportion;
s2, adding the raw materials into water for soaking, and drying in the shade after soaking to obtain a dried raw material;
s3, crushing the dried raw materials obtained in the step S2 by using a wall breaking machine to obtain crushed materials;
s4, adding the crushed material obtained in the step S3 into white spirit, and standing;
s5, artificially baking and carbonizing the raw materials which are kept still in the step S4 by using pottery in a high-temperature anaerobic environment to obtain a high-temperature anaerobic carbonized polymer;
and S6, performing secondary nano-crushing on the baked medicinal powder to obtain finished medicinal powder.
As a preferable technical scheme of the invention, in the step S2, the ratio of the raw materials to the water is 1: 4-7, and the soaking time is 10-14 hours.
As a preferable technical scheme of the invention, in the step S3, the crushing rotating speed of the wall breaking machine is not lower than 22000 r/m.
As a preferred technical scheme of the present invention, in step S4, the white spirit is prepared by fermenting 70 parts of sorghum, 5 parts of glutinous rice, 5 parts of barley, 5 parts of peas, 2 parts of sesame, 5 parts of buckwheat, 5 parts of corn and 3 parts of sweet potatoes according to a traditional solid state fermentation method, and herbal distiller' S yeast is added in the white spirit.
As a preferred technical scheme of the invention, the herbal distiller's yeast comprises rice, polygonum hydropiper, lophatherum gracile, clove, angelica, wormwood, vanilla, cinnamon, citron leaves and mulberry leaves, wherein the ratio of the rice to the polygonum hydropiper is 15: 1, and the other materials are 1/20 of the polygonum hydropiper.
In a preferred embodiment of the present invention, in step S4, the standing time is 48 hours to 72 hours.
As a preferable embodiment of the present invention, in the step S5, the baking time is not less than 4 hours.
Compared with the prior art, the invention has the beneficial effects that: the invention adopts a treatment thought for repairing an immune system, and uses corresponding eggs to treat different allergens causing allergic symptoms.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a technical scheme that: a medicine for treating poultry egg allergic diseases comprises the following components in parts by weight: 2-9 parts of poultry eggs, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
Further, the types of poultry eggs include, but are not limited to, chicken eggs, duck eggs, goose eggs, quail eggs, and egg-containing products.
Further, the poultry eggs are eggs.
Further, the specific components of the medicine are as follows: 2-9 parts of eggs, 8-22 parts of egg yolk, 4-14 parts of endothelium corneum gigeriae galli, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia root, 4-14 parts of eucommia bark, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seed and 3-10 parts of black date.
Further, the specific components of the medicine are as follows: 8 parts of eggs, 12 parts of egg yolk, 13 parts of chicken gizzard membrane, 10 parts of earthworm, 20 parts of dendrobium, 20 parts of cassia twig, 14 parts of cicada slough, 14 parts of divaricate saposhnikovia root, 13 parts of eucommia bark, 6 parts of dogwood, 10 parts of longan, 10 parts of red bean, 12 parts of Chinese torreya seed and 8 parts of black date.
As a preferred technical scheme, the poultry eggs are duck eggs.
Further, the specific components of the medicine are as follows: 2-9 parts of duck eggs, 10-20 parts of duck egg yolks, 4-10 parts of duck gizzard skins, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
Further, the specific components of the medicine are as follows: 7 parts of duck eggs, 15 parts of duck egg yolks, 10 parts of duck gizzards, 8 parts of lumbricus, 16 parts of dendrobium, 17 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 10 parts of eucommia ulmoides, 6 parts of dogwood, 6 parts of longan, 8 parts of phaseolus calcaratus, 10 parts of Chinese torreya seeds and 5 parts of black dates.
Further, the poultry eggs are goose eggs.
Further, the specific components of the medicine are as follows: 2-9 parts of goose eggs, 8-22 parts of goose egg yolk, 4-16 parts of goose gizzard-membrane, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia root, 4-14 parts of eucommia bark, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black date.
Further, the specific components of the medicine are as follows: 7 parts of goose eggs, 14 parts of goose egg yolk, 10 parts of goose gizzard-membrane, 8 parts of lumbricus, 15 parts of dendrobium, 17 parts of cassia twig, 10 parts of cicada slough, 12 parts of divaricate saposhnikovia root, 10 parts of eucommia bark, 8 parts of dogwood, 11 parts of longan, 7 parts of red bean, 6 parts of Chinese torreya seeds and 10 parts of black date.
Further, the poultry eggs are quail eggs.
Further, 2-9 parts of quail eggs, 12-22 parts of quail egg yolks, 4-14 parts of quail gizzards, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwoods, 2-12 parts of longan, 3-11 parts of red beans, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
Further, 8 parts of quail eggs, 14 parts of quail egg yolks, 10 parts of quail gizzards, 8 parts of earthworms, 22 parts of dendrobium, 18 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 12 parts of eucommia ulmoides, 6 parts of dogwood, 8 parts of longan, 7 parts of small red beans, 7 parts of Chinese torreya seeds and 7 parts of black dates.
The first embodiment is as follows: the medicine for treating the poultry egg allergic diseases comprises the following specific components: 8 parts of eggs, 12 parts of egg yolk, 13 parts of chicken gizzard membrane, 10 parts of earthworm, 20 parts of dendrobium, 20 parts of cassia twig, 14 parts of cicada slough, 14 parts of divaricate saposhnikovia root, 13 parts of eucommia bark, 6 parts of dogwood, 10 parts of longan, 10 parts of red bean, 12 parts of Chinese torreya seed and 8 parts of black date.
A processing technology of a medicine for treating poultry egg allergic diseases comprises the following steps:
s1, weighing the raw materials according to the weight proportion;
s2, adding the raw materials into water for soaking, wherein the ratio of the raw materials to the water is 1: 4, the soaking time is 11 hours, and drying in the shade after soaking to obtain a dried raw material;
s3, crushing the dried raw materials obtained in the step S2 by using a wall breaking machine, wherein the crushing speed of the wall breaking machine is not lower than 22000 r/min, and obtaining crushed materials;
s4, adding the ground material obtained in the step S3 into white spirit, and standing for 54 hours;
s5, artificially baking and carbonizing the raw materials which are kept still in the step S4 by using pottery in a high-temperature anaerobic environment to obtain a high-temperature anaerobic carbonized polymer, wherein the baking time is 6 hours;
and S6, performing secondary nano-crushing on the baked medicinal powder to obtain finished medicinal powder.
Example two: the medicine for treating the poultry egg allergic diseases comprises the following specific components: 7 parts of duck eggs, 15 parts of duck egg yolks, 10 parts of duck gizzards, 8 parts of lumbricus, 16 parts of dendrobium, 17 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 10 parts of eucommia ulmoides, 6 parts of dogwood, 6 parts of longan, 8 parts of phaseolus calcaratus, 10 parts of Chinese torreya seeds and 5 parts of black dates.
A processing technology of a medicine for treating poultry egg allergic diseases comprises the following steps:
s1, weighing the raw materials according to the weight proportion;
s2, adding the raw materials into water for soaking, wherein the ratio of the raw materials to the water is 1: 7, the soaking time is 11 hours, and drying in the shade after soaking to obtain a dried raw material;
s3, crushing the dried raw materials obtained in the step S2 by using a wall breaking machine, wherein the crushing speed of the wall breaking machine is not lower than 22000 r/min, and obtaining crushed materials;
s4, adding the crushed material obtained in the step S3 into white spirit, and standing for 64 hours;
s5, artificially baking and carbonizing the raw materials which are kept still in the step S4 by using pottery in a high-temperature anaerobic environment to obtain a high-temperature anaerobic carbonized polymer, wherein the baking time is 4 hours;
and S6, performing secondary nano-crushing on the baked medicinal powder to obtain finished medicinal powder.
Example three: the medicine for treating the poultry egg allergic diseases comprises the following specific components: 7 parts of goose eggs, 14 parts of goose egg yolk, 10 parts of goose gizzard-membrane, 8 parts of lumbricus, 15 parts of dendrobium, 17 parts of cassia twig, 10 parts of cicada slough, 12 parts of divaricate saposhnikovia root, 10 parts of eucommia bark, 8 parts of dogwood, 11 parts of longan, 7 parts of red bean, 6 parts of Chinese torreya seeds and 10 parts of black date.
A processing technology of a medicine for treating poultry egg allergic diseases comprises the following steps:
s1, weighing the raw materials according to the weight proportion;
s2, adding the raw materials into water for soaking, wherein the ratio of the raw materials to the water is 1: 7, the soaking time is 11 hours, and drying in the shade after soaking to obtain a dried raw material;
s3, crushing the dried raw materials obtained in the step S2 by using a wall breaking machine, wherein the crushing speed of the wall breaking machine is not lower than 22000 r/min, and obtaining crushed materials;
s4, adding the crushed material obtained in the step S3 into white spirit, and standing for 64 hours;
s5, artificially baking and carbonizing the raw materials which are kept still in the step S4 by using pottery in a high-temperature anaerobic environment to obtain a high-temperature anaerobic carbonized polymer, wherein the baking time is 4 hours;
and S6, performing secondary nano-crushing on the baked medicinal powder to obtain finished medicinal powder.
Example four: the medicine for treating the poultry egg allergic diseases comprises the following specific components: 8 parts of quail eggs, 14 parts of quail egg yolks, 10 parts of quail gizzards, 8 parts of earthworms, 22 parts of dendrobium, 18 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 12 parts of eucommia ulmoides, 6 parts of dogwood, 8 parts of longan, 7 parts of phaseolus calcaratus, 7 parts of Chinese torreya seeds and 7 parts of black dates.
A processing technology of a medicine for treating poultry egg allergic diseases comprises the following steps:
s1, weighing the raw materials according to the weight proportion;
s2, adding the raw materials into water for soaking, wherein the ratio of the raw materials to the water is 1: 7, the soaking time is 11 hours, and drying in the shade after soaking to obtain a dried raw material;
s3, crushing the dried raw materials obtained in the step S2 by using a wall breaking machine, wherein the crushing speed of the wall breaking machine is not lower than 22000 r/min, and obtaining crushed materials;
s4, adding the crushed material obtained in the step S3 into white spirit, and standing for 64 hours;
s5, artificially baking and carbonizing the raw materials which are kept still in the step S4 by using pottery in a high-temperature anaerobic environment to obtain a high-temperature anaerobic carbonized polymer, wherein the baking time is 4 hours;
and S6, performing secondary nano-crushing on the baked medicinal powder to obtain finished medicinal powder.
The differences between the first embodiment, the second embodiment, the third embodiment and the fourth embodiment are that the selected egg components are different, and the component ratios are different.
200 cases of egg allergic disease patients are selected, wherein 114 male patients and 86 female patients with different ages of 25-65 are divided into five groups, and the conditions of the five groups have no significant difference; the first comparative example and the second comparative example adopt conventional drug treatment, and the first example, the second example, the third example and the fourth example adopt corresponding drug treatment; the effect table is as follows:
| total number (case) | Invalid (example) | Effective (example) | Effective rate (%) | Relapse example (example) | Recurrence Rate (%) | |
| Comparative example 1 | 40 | 6 | 34 | 85.0 | 8 | 20.0 |
| Comparative example No. two | 40 | 8 | 32 | 80.0 | 9 | 22.5 |
| Example one | 40 | 3 | 37 | 92.5 | 1 | 2.5 |
| Example two | 40 | 2 | 38 | 95.0 | 2 | 5.0 |
| EXAMPLE III | 40 | 2 | 38 | 95.0 | 1 | 2.5 |
| Example four | 40 | 1 | 39 | 97.5 | 2 | 5.0 |
The failure is the non-improvement of the symptoms of the patient, the effective is the disappearance of the symptoms of the patient, and the recurrence is the reoccurrence of the disease two weeks after the treatment.
It can be intuitively analyzed from the graph that the efficiency of the examples provided by the present invention is much higher than that of the comparative examples one and two, and the recurrence rate is much lower than that of the comparative examples one and two.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (21)
1. A medicine for treating poultry egg allergic diseases is characterized in that: the composition consists of the following components in parts by weight: 2-9 parts of poultry eggs, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
2. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: the egg types include, but are not limited to, chicken, duck, goose, quail and egg-containing products.
3. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: the poultry eggs are eggs.
4. The medicament for treating the poultry egg allergic disease according to claim 3, which is characterized in that: the medicine comprises the following specific components: 2-9 parts of eggs, 8-22 parts of egg yolk, 4-14 parts of endothelium corneum gigeriae galli, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia root, 4-14 parts of eucommia bark, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seed and 3-10 parts of black date.
5. The medicament for treating the poultry egg allergic disease according to claim 4, which is characterized in that: the medicine comprises the following specific components: 8 parts of eggs, 12 parts of egg yolk, 13 parts of chicken gizzard membrane, 10 parts of earthworm, 20 parts of dendrobium, 20 parts of cassia twig, 14 parts of cicada slough, 14 parts of divaricate saposhnikovia root, 13 parts of eucommia bark, 6 parts of dogwood, 10 parts of longan, 10 parts of red bean, 12 parts of Chinese torreya seed and 8 parts of black date.
6. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: the poultry eggs are duck eggs.
7. The medicament for treating the poultry egg allergic disease according to claim 6, which is characterized in that: the medicine comprises the following specific components: 2-9 parts of duck eggs, 10-20 parts of duck egg yolks, 4-10 parts of duck gizzard skins, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
8. The medicament for treating the poultry egg allergic disease according to claim 7, which is characterized in that: the medicine comprises the following specific components: 7 parts of duck eggs, 15 parts of duck egg yolks, 10 parts of duck gizzards, 8 parts of lumbricus, 16 parts of dendrobium, 17 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 10 parts of eucommia ulmoides, 6 parts of dogwood, 6 parts of longan, 8 parts of phaseolus calcaratus, 10 parts of Chinese torreya seeds and 5 parts of black dates.
9. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: the poultry eggs are goose eggs.
10. The medicament for treating the poultry egg allergic disease according to claim 9, which is characterized in that: the medicine comprises the following specific components: 2-9 parts of goose eggs, 8-22 parts of goose egg yolk, 4-16 parts of goose gizzard-membrane, 5-12 parts of lumbricus, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia root, 4-14 parts of eucommia bark, 2-8 parts of dogwood, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black date.
11. The medicament for treating the allergic disease of the poultry eggs, according to claim 10, is characterized in that: the medicine comprises the following specific components: 7 parts of goose eggs, 14 parts of goose egg yolk, 10 parts of goose gizzard-membrane, 8 parts of lumbricus, 15 parts of dendrobium, 17 parts of cassia twig, 10 parts of cicada slough, 12 parts of divaricate saposhnikovia root, 10 parts of eucommia bark, 8 parts of dogwood, 11 parts of longan, 7 parts of red bean, 6 parts of Chinese torreya seeds and 10 parts of black date.
12. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: the poultry egg is quail egg.
13. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: 2-9 parts of quail eggs, 12-22 parts of quail egg yolks, 4-14 parts of quail gizzards, 5-12 parts of earthworms, 11-26 parts of dendrobium, 11-21 parts of cassia twig, 4-16 parts of cicada slough, 8-16 parts of divaricate saposhnikovia roots, 4-14 parts of eucommia ulmoides, 2-8 parts of dogwoods, 2-12 parts of longan, 3-11 parts of phaseolus calcaratus, 2-14 parts of Chinese torreya seeds and 3-10 parts of black dates.
14. The medicament for treating the poultry egg allergic disease according to claim 1, which is characterized in that: 8 parts of quail eggs, 14 parts of quail egg yolks, 10 parts of quail gizzards, 8 parts of earthworms, 22 parts of dendrobium, 18 parts of cassia twig, 12 parts of cicada slough, 12 parts of divaricate saposhnikovia roots, 12 parts of eucommia ulmoides, 6 parts of dogwood, 8 parts of longan, 7 parts of phaseolus calcaratus, 7 parts of Chinese torreya seeds and 7 parts of black dates.
15. The process for preparing a medicament for treating allergic diseases in poultry eggs according to any one of claims 1 to 14, wherein the process comprises the following steps:
s1, weighing the raw materials according to the weight proportion;
s2, adding the raw materials into water for soaking, and drying in the shade after soaking to obtain a dried raw material;
s3, crushing the dried raw materials obtained in the step S2 by using a wall breaking machine to obtain crushed materials;
s4, adding the crushed material obtained in the step S3 into white spirit, and standing;
s5, artificially baking and carbonizing the raw materials which are kept still in the step S4 by using pottery in a high-temperature anaerobic environment to obtain a high-temperature anaerobic carbonized polymer;
and S6, performing secondary nano-crushing on the baked medicinal powder to obtain finished medicinal powder.
16. The process for preparing a medicament for treating allergic diseases in poultry eggs according to claim 15, wherein the process comprises the following steps: in the step S2, the ratio of the raw materials to the water is 1: 4-7, and the soaking time is 10-14 hours.
17. The process for preparing a medicament for treating allergic diseases in poultry eggs according to claim 15, wherein the process comprises the following steps: in the step S3, the crushing speed of the wall breaking machine is not lower than 22000 r/min.
18. The process for preparing a medicament for treating allergic diseases in poultry eggs according to claim 15, wherein the process comprises the following steps: in the step S4, the Chinese liquor is prepared by fermenting 70 parts of sorghum, 5 parts of glutinous rice, 5 parts of barley, 5 parts of peas, 2 parts of sesame, 5 parts of buckwheat, 5 parts of corn and 3 parts of sweet potatoes according to a traditional solid state fermentation method, and herbal distiller yeast is added in the Chinese liquor.
19. The process for preparing a medicament for treating allergic diseases in poultry eggs according to claim 15, wherein the process comprises the following steps: the herbal distiller's yeast comprises rice, herba Polygoni Hydropiperis, folium Bambusae, flos Caryophylli, radix Angelicae sinensis, folium Artemisiae Argyi, herb Hierochloes Adoratae, cortex Cinnamomi Japonici, fructus Citri leaves, and folium Mori, wherein the ratio of rice and herba Polygoni Hydropiperis is 15: 1, and other materials are 1/20 of herba Polygoni Hydropiperis.
20. The process for preparing a medicament for treating allergic diseases in poultry eggs according to claim 15, wherein the process comprises the following steps: in the step S4, the standing time is 48-72 hours.
21. The process for preparing a medicament for treating allergic diseases in poultry eggs according to claim 15, wherein the process comprises the following steps: in the step S5, the baking time is not less than 4 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911245945.9A CN112915160A (en) | 2019-12-08 | 2019-12-08 | Medicine for treating poultry egg allergic diseases and processing technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911245945.9A CN112915160A (en) | 2019-12-08 | 2019-12-08 | Medicine for treating poultry egg allergic diseases and processing technology thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112915160A true CN112915160A (en) | 2021-06-08 |
Family
ID=76162028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911245945.9A Pending CN112915160A (en) | 2019-12-08 | 2019-12-08 | Medicine for treating poultry egg allergic diseases and processing technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112915160A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586583A (en) * | 2004-07-07 | 2005-03-02 | 香港养春堂中药有限公司 | Desensitization tablet |
-
2019
- 2019-12-08 CN CN201911245945.9A patent/CN112915160A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586583A (en) * | 2004-07-07 | 2005-03-02 | 香港养春堂中药有限公司 | Desensitization tablet |
Non-Patent Citations (1)
| Title |
|---|
| 李彦军: "马淑然运用加味过敏煎治疗过敏性疾病验案举隅" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104208673B (en) | A kind of fowl antiviral composition, lyophilized powder, preparation method and application | |
| CN104800819B (en) | A kind of Chinese medicine preparation for treating checken pest | |
| CN102153668A (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| CN104363773B (en) | For treating herbal-composition of gastroenteritis disease and its production and use | |
| CN112915160A (en) | Medicine for treating poultry egg allergic diseases and processing technology thereof | |
| CN113018382A (en) | Medicine for treating milk allergic diseases and processing technology thereof | |
| CN112915161A (en) | Medicine for treating shell allergic diseases and processing technology thereof | |
| CN112915159A (en) | Medicine for treating allergic diseases of animal meat and processing technology thereof | |
| CN113018381A (en) | Medicine for treating vegetable allergic diseases and processing technology thereof | |
| CN112915163A (en) | Medicine for treating allergic diseases of plant seeds and processing technology thereof | |
| CN112915168A (en) | Medicine for treating grain allergic diseases and processing technology thereof | |
| CN112915162A (en) | Medicine for treating allergic diseases of nuts and processing technology thereof | |
| CN102697887A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN104208683B (en) | The pharmaceutical composition of a kind of anti-duck viral disease, lyophilized powder, preparation method and application | |
| CN113018390A (en) | Medicine for treating alcohol allergic diseases and processing technology thereof | |
| Ardiyanto et al. | Clinical trial of osteoarthritis jamu formula compare to piroxicam | |
| CN105796928A (en) | Traditional Chinese medicine composition for treating avian coccidiosis | |
| CN112915164A (en) | Medicine for treating fruit allergic diseases and processing technology thereof | |
| CN116474014B (en) | Traditional Chinese medicine composition for treating chicken histomonas and preparation method thereof | |
| CN1582989A (en) | Medicine for hyperplasia of mammary glands and its preparation | |
| CN109498701A (en) | A kind of Chinese medicine composition and its preparation method and application for preventing and treating goose paramyxovirus | |
| CN116036188B (en) | Traditional Chinese medicine composition for preventing and treating chicken coccidiosis as well as preparation method and application thereof | |
| CN1316980C (en) | Medicinal use of spanish moss of Chinese traditional medicine | |
| Feizi et al. | The effects of Echinacea purpurea dried extract on humoral immune response of broiler chicks to Newcastle vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210608 |
|
| RJ01 | Rejection of invention patent application after publication |